Navigation Links
Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
Date:5/7/2008

compounds target G protein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the continuation of the collaboration between Arena and Taisho and efforts thereunder; the progress of a Phase 1 clinical trial program under such collaboration, including future results, activities and related payments; the therapeutic, commercial and other potential of the compound in such clinical trial program; and other statements about Arena's outlook, strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, the results of clinical trials or preclinical studies may not be predictive of future results, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents, the timing and receipt of payments and fees, if any, from Arena's collaborators, and Arena's ability to redeem with common stock any outstanding
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
10. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
11. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... N.C. , May 22, 2015  Research ... hosting its sixth Medical Affairs Roundtable ... (EDT) via a virtual roundtable to discuss "Medical ... Best Practices, Medical Affairs Consortium provides ... insights about the key challenges they face. The ...
(Date:5/22/2015)... The Taskforce representing Canada,s living victims ... that the Minister and Health Canada have put into this ... needs of the thalidomide survivors, and more than 70% of ... with annual adjustments for inflation. Certain of the ... based on the severity of their disability, tax free, with ...
(Date:5/22/2015)... , May 22, 2015  Amgen (NASDAQ: ... has commenced termination of its participation in ... AstraZeneca (LON:AZN, STO:AZN and NYSE: AZN ... in development for patients with moderate-to-severe plaque ... decision was based on events of suicidal ...
Breaking Medicine Technology:Best Practices Sixth Medical Affairs Consortium Roundtable to Focus on Health Economics & Outcomes Research 2Amgen to terminate participation in co-development and commercialization of brodalumab 2Amgen to terminate participation in co-development and commercialization of brodalumab 3Amgen to terminate participation in co-development and commercialization of brodalumab 4Amgen to terminate participation in co-development and commercialization of brodalumab 5
... Corporation ( www.fluidnet.net ), an innovator of advanced intravenous ... Directors has unanimously appointed Benjamin E. Bulkley as President ... company,s Founder, Jeffrey Carlisle, who will serve as Fluidnet,s ... Board of Directors, Chuck Hadley, Chairman, said, "Fluidnet is ...
... Bulletin Board: IAGX ) announced today that based on ... of August that it expects its net sales for its second ... $2.8 to $3.2 million, an increase of 158% to 195% compared ... compared to the second quarter of the previous fiscal year. ...
Cached Medicine Technology:Fluidnet Corporation Appoints Benjamin E. Bulkley President and Chief Executive Officer 2Imagenetix, Inc. Provides Net Sales Guidance for the Second Quarter Fiscal 2011 2Imagenetix, Inc. Provides Net Sales Guidance for the Second Quarter Fiscal 2011 3
(Date:5/25/2015)... 2015 After the sensational buzz surrounding ... human wellness company Trivedi Master Wellness™ agrees ... world-class series titled, “Consciousness is Power.” Presently, the Live-Streaming ... 2015 at the routinely allotted time from 10:00pm PST/1:00pm ... be made available to the public and accessible on ...
(Date:5/24/2015)... The Rolling Stones Zip Code summer stadium ... Petco Park. This iconic group is ready for their ... had a warmup show in Los Angeles at the Henry ... this beloved band not only played their Sticky Fingers album ... "Jumping Jack Flash," "Moonlight Mile" and "All Down the ...
(Date:5/24/2015)... May 24, 2015 EnviroLeather™ by ... “InkGard™ Plus” – a classic, rugged leather grain ... allowing difficult stains, including ink, to be easily ... colors suitable for corporate, healthcare, hospitality and education ... with EnviroLeather’s goal of developing products that are ...
(Date:5/24/2015)... WI (PRWEB) May 24, 2015 ... Health System CEO - The ... and honored at the fourth annual ... April 15 at Geneva National in ... school): ,     -Badger High School,         Jonathan ...
(Date:5/23/2015)... 2015 With the implementation of the ... it increasingly difficult to provide their employees with a ... adequate insurance for employees stand to face strict penalties. ... integral part of a business’s success or failure. In ... Online USA Doctors has created a varying level of ...
Breaking Medicine News(10 mins):Health News:Hundreds of People Are Thrilled to Hear that Trivedi Master Wellness™ Promises to Hold Another Workshop in June 2015 2Health News:Hundreds of People Are Thrilled to Hear that Trivedi Master Wellness™ Promises to Hold Another Workshop in June 2015 3Health News:The Rolling Stones Tickets in San Diego, Orlando, Minneapolis, Dallas, Pittsburgh, Indianapolis, Atlanta, Detroit, Milwaukee, Kansas City, Columbus, Nashville & Raleigh 2Health News:EnviroLeather By LDI Launches "InkGard Plus" - Stain Resistant Faux Leather 2Health News:Mercy Foundation Honors 16 Students for Making a Difference - Mercy Health System Javon Bea 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3
... who are smokers and have a family history of brain aneurysm ... a brain aneurysm themselves. The research is published in the December ... of the American Academy of Neurology and will appear in the ... type of stroke, called subarachnoid hemorrhage, is one of the bleeding ...
... Priority in 2009SPRINGFIELD, Ill., Dec. 31 The following is ... Illinois:The economic situation is forcing more Illinois families to face ... of people are cutting back on necessities in order to ... it,s too expensive. High health care costs are leaving ...
... mcg/hr) Not Affected RARITAN, N.J., Dec. 31 PriCara(R), ... lot of 50 microgram/hour (mcg/hr) DURAGESIC(R) (fentanyl transdermal system) ... and one lot of 50 mcg/hr fentanyl patches sold ... voluntarily recalled as a precaution from wholesalers and pharmacies. ...
... XStor Medical Systems, a,privately held Silicon Valley ... advanced clinical applications and collaborative patient care.,The ... participating,hospitals, clinics, and healthcare systems to securely ... and patients. The,XStor Imaging Platform is a ...
... Watson Pharmaceuticals, Inc. (NYSE: WPI ), ... today announced that its subsidiary, Watson Laboratories, Inc., ... and Drug Administration to market its over-the-counter Nicotine ... 2 mg and 4 mg strengths.Nicotine Polacrilex Gum, ...
... deprivation therapy that prostate cancer patients often take gives them ... within a couple of years. Now, researchers at Johns Hopkins ... cancer cells in patients who no longer respond to this ... Cancer Research , could lead to a way to ...
Cached Medicine News:Health News:Smokers with stroke in the family 6 times more likely to have stroke too 2Health News:PriCara(R) Recalls 50 mcg/hr DURAGESIC(R) (fentanyl transdermal system) CII Pain Patches 2Health News:PriCara(R) Recalls 50 mcg/hr DURAGESIC(R) (fentanyl transdermal system) CII Pain Patches 3Health News:XStor Medical Systems Announces the Release of its Imaging Platform for Connectivity Between Healthcare Enterprises 2Health News:Watson Pharmaceuticals Receives FDA Approval for Mint Coated Nicotine Gum 2Health News:Why prostate cancer patients fail hormone deprivation therapy 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: